XtalPi

XtalPi is an AI-driven drug discovery company leveraging quantum physics algorithms, artificial intelligence, and robotics to accelerate pharmaceutical research. Founded by three MIT quantum physicists, the company uses quantum calculations for molecular structures to train proprietary AI large language models that screen billions of molecules for drug candidates, increasing chemical experiment success rates from 20-30% to 90%. XtalPi serves nearly 80% of global big pharma including Pfizer, Eli Lilly, Johnson & Johnson, and Merck, with a $6 billion collaboration with DoveTree Medicines announced in 2025.